Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02133248 · ClinicalTrials.gov registry record
Identification of Donor Specific B Cells and Antibody Mediated Rejection
A clinical trial, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- 86
- Enrollment target
NCT02133248: Clinical Trial study, sponsored by University of Wisconsin, Madison.
NCT02133248 is a clinical trial that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 86 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02133248 was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- 86 participants
- Enrollment target
Study Summary
Many people who are on the wait list for a kidney transplant have harmful antibodies, called donor specific antibodies (DSA), which will attack foreign tissue such as the transplanted organ. These people are considered to be"sensitized". Prior to receiving a kidney, these patients undergo desensitization treatments to remove these harmful antibodies. Levels of DSA are measured after desensitization, but the cells that produce the DSA, donor specific B cells (DSB), have not generally been measured. Additionally, if a person experiences chronic rejection due to antibodies they are also desensitized, but only the DSA are measured. This study will measure the DSA and, using new techniques, the DSB in two study groups: those who are receiving an organ and those experiencing chronic antibody mediated rejection after receiving an organ. The hypothesis is people with higher levels of DSB after desensitization are more likely to develop antibody mediated rejection.
Primary Outcome
The primary objective of this study is to determine whether desensitization results in not only a decrease in anti-HLA antibodies, but also a decrease in donor specific B cell populations.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2014-06-05 |
| Est. Completion | 2021-11-17 |
Why NCT02133248 stopped before completion
NCT02133248 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 86 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02133248 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02133248 about?
NCT02133248 is a clinical study titled "Identification of Donor Specific B Cells and Antibody Mediated Rejection". Many people who are on the wait list for a kidney transplant have harmful antibodies, called donor specific antibodies (DSA), which will attack foreign tissue such as the transplanted organ. These people are considered to be"sensitized". Prior to receiving a kidney, these patients undergo desensitiz...
What is the current status of trial NCT02133248?
This trial is currently terminated. The enrollment target is 86 participants. The study started on 2014-06-05. Estimated completion is 2021-11-17.
Who is sponsoring clinical trial NCT02133248?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI